APUS (Apimeds Pharmaceuticals US, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by APUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-21 | Inscobee Inc. | 10%+ Owner | — | — | — |
| 2025-11-13 | CAROL A O'DONNELL | Director | A | — | — |
| 2025-11-13 | Elona Kogan | Director | A | — | — |
| 2025-11-13 | Bennett Weintraub | Director | A | — | — |
| 2025-11-13 | Jakap Koo | Director | A | — | — |
| 2025-11-13 | Hankil Yoon | Director | A | — | — |
| 2025-10-24 | Elona Kogan | Director | A | — | — |
| 2025-10-21 | CAROL A O'DONNELL | Director | A | — | — |
| 2025-10-17 | Jakap Koo | Director | A | — | — |
| 2025-10-17 | Hankil Yoon | Director | A | — | — |
| 2025-10-17 | Bennett Weintraub | Director | A | — | — |
| 2025-10-17 | Erik C. Emerson | Chief Executive Officer | A | — | — |
| 2025-10-17 | Christopher Kim | Chairman and CMO | A | — | — |
| 2025-06-11 | Inscobee Inc. | 10%+ Owner | C | — | — |
| 2025-05-20 | Bennett Weintraub | Director | A | — | — |
| 2025-05-20 | Jakap Koo | Director | A | — | — |
| 2025-05-20 | Christopher Kim | Chairman and CMO | A | — | — |
| 2025-05-20 | Erik C. Emerson | Chief Executive Officer | A | — | — |
| 2025-05-20 | Hankil Yoon | Director | A | — | — |
| 2025-05-20 | Elona Kogan | Director | A | — | — |
| 2025-05-20 | CAROL A O'DONNELL | Director | A | — | — |
| 2025-05-15 | Christopher Kim | Chairman and CMO | Buy | — | — |
| 2025-05-14 | Jakap Koo | Director | Buy | — | — |
| 2025-05-14 | Inscobee Inc. | 10%+ Owner | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 637,233 | — |
| — | Chief Executive Officer | 75,000 | — |
| — | Director | 64,388 | — |
| — | Chairman and CMO | 27,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APUS quote page; the site-wide leaderboard is on the insider transactions hub.